The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer

Christopher Darr, Ulrich Krafft, Boris Hadaschik, Stephan Tschirdewahn, Sabina Sevcenco, Anita Csizmarik, Peter Nyirady, Zsófia Küronya, Henning Reis, Agnieszka Maj-Hes, Shahrokh F. Shariat, Gero Kramer, Tibor Szarvas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: High baseline YKL-40 serum levels are associated with drug resistance in several solid tumours. However, their role in predicting docetaxel (DOC) resistance in prostate cancer (PCa) is unknown. Methods: Pre-treatment serum levels of YKL-40 and prostate-specific antigen (PSA) were analyzed in 109 castration-resistant prostate cancer patients who underwent DOC-therapy. Responsive patients were retreated by repeated series of DOC. Results were compared with the clinical parameters as well as overall (OS) and disease-specific survival (DSS). Results: YKL-40 but not PSA serum levels were significantly higher in patients with baseline resistance to DOC (p = 0.035). Higher YKL-40 and PSA levels were detected in patients with bone metastasis (p = 0.032; p = 0.010) and in those who were not pre-treated with radical prostatectomy (p = 0.011, p = 0.008). High YKL-40 levels were associated with shorter OS (p = 0.037) and DSS (p = 0.017) in patients who received DOC in the first-line setting. In multivariable analysis, ECOG performance status (p = 0.009), presence of any metastases (p = 0.016) and high PSA levels (p = 0.005) remained independent predictors for DSS. Conclusions: YKL-40 may help to identify patients with baseline resistance to DOC and therefore may help to optimize treatment decisions. In accordance, high pre-treatment YKL-40 serum levels were associated with shorter OS and DSS in patients who received DOC as first-line therapy.

Original languageEnglish
Pages (from-to)65-73
Number of pages9
JournalUrologia Internationalis
Volume101
Issue number1
DOIs
Publication statusPublished - Jul 1 2018

Keywords

  • Castratation-resistant prostate cancer
  • Docetaxel
  • Drug resistance
  • Prognosis
  • Prostate cancer
  • YKL-40

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Darr, C., Krafft, U., Hadaschik, B., Tschirdewahn, S., Sevcenco, S., Csizmarik, A., Nyirady, P., Küronya, Z., Reis, H., Maj-Hes, A., Shariat, S. F., Kramer, G., & Szarvas, T. (2018). The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. Urologia Internationalis, 101(1), 65-73. https://doi.org/10.1159/000489891